Meeting
2022 ASCO Annual Meeting
A phase 1b lead-in to a randomized phase 2 trial of lurbinectedin plus doxorubicin in leiomyosarcoma (LMS).
Authors
Gregory Michael Cote
MGH, Boston, MA
Gregory Michael Cote , Edwin Choy , Katherine Anne Thornton , Emanuele Mazzola , Sara Bouberhan , Priscilla Merriam , Andrew J. Wagner , Jeffrey A. Morgan , Candace L. Haddox , Jay Oza , George D. Demetri , Suzanne George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT05099666
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS11592)
DOI
10.1200/JCO.2022.40.16_suppl.TPS11592
Abstract #
TPS11592
Poster Bd #
491a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
TTI-621-03: A phase I/II study of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma (LMS).
First Author: Sant P. Chawla
Poster
2022 ASCO Annual Meeting
A phase II study of gemcitabine docetaxel combination in metastatic/unresectable locally advanced relapsed synovial sarcoma.
First Author: Ghazal Tansir
Poster
2021 ASCO Annual Meeting
Updated results of European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 1202 cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma.
First Author: Roberta Sanfilippo
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo